Myogenin and MyoD1 expression in paediatric rhabdomyosarcomas

Journal of Clinical Pathology

Volumn 56, Issue 6, 2003, Pages 412-416

  Sebire, N J ^a   Malone, M ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; DESMIN; DNA BINDING PROTEIN; EPITOPE; MYOD1 PROTEIN; MYOGENIN;

BRIGHT FIELD MICROSCOPY; CELL DIFFERENTIATION; CELL SPECIFICITY; CHROMOSOME 11Q; CHROMOSOME 1P; CHROMOSOME TRANSLOCATION; CYTOARCHITECTURE; CYTOLOGY; DISEASE MARKER; FUSION GENE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMEDIATE FILAMENT; MUSCLE DEVELOPMENT; NORTHERN BLOTTING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RHABDOMYOSARCOMA; SYNDROME DELINEATION; TETRAPLOIDY; TISSUE FIXATION; TISSUE SECTION; WILD TYPE;

EID: 0037634085     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.56.6.412     Document Type: Review

References (64)

1. O'Shea PA. Myogenic tumors of soft tissue. In: Coffin CM, Dehner LP, ed. Pediatric soft tissue tumors. Baltimore: Williams & Wilkins, 1997:214-53.
2. Parham DM. Pathologic classification of rhabdomyosarcomas and correlations with molecular studies. Mod Pathol 2001;14:506-14.
3. Weiss SW, Goldblum JR. General considerations. In: Weiss SW, Goldblum JR, eds. Enzinger and Weiss's soft tissue tumors. St Louis: Mosby, 2001:1-19.
4. Pappo AS, Shapiro DN, Crist WM, et al. Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol 1995;13:2123-39.
5. Galili N, Davis RJ, Fredericks WJ, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993;5:230-5.
6. Shapiro DN, Sublett JE, Li B, et al. Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. Cancer Res 1993;53:5108-12.
7. Barr FG, Galili N, Holick J, et al. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993;3:113-17.
8. Davis RJ, D'Cruz CM, Lovell MA, et al. Fusion of PAX7 to FKHR by the va riant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 1994;54:2869-72.
9. Douglass EC, Shapiro DN, Valentine M, et al. Alveolar rhabdomyosarcoma with the t(2;13): cytogenetic findings and clinicopathologic correlations. Med Pediatr Oncol 1993;21:83-7.
10. Whang-Peng J, Knutsen T, Theil K, et al. Cytogenetic studies in subgroups of rhabdomyosarcoma. Genes Chromosomes Cancer 1992;5:299-310.
11. Barr FG, Holick J, Nycum L, et al. Localization of the t(2;13) breakpoint of alveolar rhabdomyosarcoma on a physical map of chromosome 2. Genomics 1992;13:1150-6.
12. Shapiro DN, Valentine MB, Sublett JE, et al. Chromosomal sublocalization of the 2;13 translocation breakpoint in alveolar rhabdomyosarcoma. Genes Chromosomes Cancer 1992;4:241-9.
13. Dal Cin P, Brock P, Aly MS, et al. A variant (2;13) translocation in rhabdomyosarcoma. Cancer Genet Cytogenet 1991;55:191-5.
14. Mitchell CD, Ventris JA, Warr TJ, et al. Molecular definition in a somatic cell hybrid of a specific 2:13 translocation breakpoint in childhood rhabdomyosarcoma. Oncogene 1991;6:89-92.
15. Nojima T, Abe S, Yamaguchi H, et al. A case of alveolar rhabdomyosarcoma with o chromosomal translocation, t(2;13)(q37;q14). Virchows Arch A Pathol Anat Histopathol 1990;417:357-9.
16. Rowe D, Gerrard M, Gibbons B, et al. Two further cases of t(2;13) in alveolar rhabdomyosarcoma indicating a review of the published chromosome breakpoints. Br J Cancer 1987;56:379-80.
17. Lizard-Nacol S, Mugneret F, Volk C, et al. Translocation (2;13)(q37;q14) in alveolar rhabdomyosarcoma: a new case. Cancer Genet Cytogenet 1987;25:373-4.
18. Lai JL, Savary JB, Deminatti M, et al. Translocation (2;13)(q37;q14) in rhabdomyosarcoma: a new case. Cancer Genet Cytogenet 1987;25:371-2.
19. Douglass EC, Valentine M, Etcubanas E, et al. A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet Cell Genet 1987;45:148-55.
20. Douglass EC, Rowe ST, Valentine M, et al. Variant translocations of chromosome 13 in alveolar rhabdomyosarcoma. Genes Chromosomes Cancer 1991;3:480-2.
21. Biegel JA, Meek RS, Parmiter AH, et al. Chromosomal translocation t(1;13)(p36;q14) in a case of rhabdomyosarcoma. Genes Chromosomes Cancer 1991;3:483-4.
22. Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 2002;20:2672-9.
23. Anderson J, Gordon T, McManus A, et al. Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome? Br J Cancer 2001;85:831-5.
24. Edwards RH, Chatten J, Xiong QB, et al. Detection of gene fusions in rhabdomyosarcoma by reverse transcriptase-polymerase chain reaction assay of archival samples. Diagn Mol Pathol 1997;6:91-7.
25. Reichmuth C, Markus MA, Hillemanns M, et al. The diagnostic potential of the chromosome translocation t[2;13) in rhabdomyosarcoma: a PCR study of fresh-frozen and paraffin-embedded tumour samples. J Pathol 1996;180:50-7.
26. Arden KC, Anderson MJ, Finckenstein FG, et al. Detection of the t(2;13) chromosomal translocation in alveolar rhabdomyosarcoma using the reverse transcriptase-polymerase chain reaction. Genes Chromosomes Cancer 1996;16:254-60.
27. Anderson J, Renshaw J, McManus A, et al. Amplification of the t(2;13) and t(1;13) translocations of alveolar rhabdomyosarcoma in small formalin-fixed biopsies using a modified reverse transcriptase polymerase chain reaction. Am J Pathol 1997;150:477-82.
28. Gordon T, McManus A, Anderson J, et al. Cytogenetic abnormalities in 42 rhabdomyosarcoma: a United Kingdom cancer cytogenetics group study. Med Pediatr Oncol 2001;36:259-67.
29. Frascella E, Toffolatti L, Rosolen A. Normal and rearranged PAX3 expression in human rhabdomyosarcoma. Cancer Genet Cytogenet 1998;102:104-9.
30. Kenet G, Sharon N, Rosner E, et al. Chromosomal translocation (1:13) in a case of alveolar rhabdomyosarcoma. J Pediatr Hematol Oncol 1998;20:86-7.
31. Grundy R, Anderson J, Gaze M, et al. Congenital alveolar rhabdomyosarcoma: clinical and molecular distinction from alveolar rhabdomyosarcoma in older children. Cancer 2001;91:606-12.
32. Kullendorff CM, Donner M, Mertens F, et al. Chromosomal aberrations in a consecutive series of childhood rhabdomyosarcoma. Med Pediatr Oncol 1998;30:156-9.
33. Bernasconi M, Remppis A, Fredericks WJ, et al. Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc Natl Acad Sci U S A 1996;93:13164-9.
34. Fredericks WJ, Galili N, Mukhopadhyay S, et al. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol 1995;15:1522-35.
35. Bennicelll JL, Edwards RH, Barr FG. Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma. Proc Natl Acad Sci U S A 1996;93:5455-9.
36. Davis RJ, Barr FG. Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma. Proc Natl Acad Sci U S A 1997;94:8047-51.
37. Barr FG, Nauta LE, Davis RJ, et al. In vivo amplification of the PAX3-FKHR and PAX7-FKHR fusion genes in alveolar rhabdomyosarcoma. Hum Mol Genet 1996;5:15-21.
38. Sublett JE, Jeon IS, Shapiro DN. The alveolar rhabdomyosarcoma PAX3/FKHR fusion protein is a transcriptional activator. Oncogene 1995;11:545-52.
39. Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 2001;20:5736-46.
40. Fitzgerald JC, Scherr AM, Barr FG. Structural analysis of PAX7 rearrangements in alveolar rhabdomyosarcoma. Cancer Genet Cytogenet 2000;117:37-40.
41. Anderson J, Ramsay A, Gould S, et al. PAX3-FKHR induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcoma. Am J Pathol 2001;159:1089-96.
42. Collins MH, Zhao H, Womer RB, et al. Proliferative and apoptotic differences between alveolar rhabdomyosarcoma subtypes: a comparative study of tumors containing PAX3-FKHR or PAX7-FKHR gene fusions. Med Pediatr Oncol 2001;37:83-9.
43. Wright WE, Sassoon DA, Lin VK. Myogenin, a factor regulating myogenesis, has a domain homologous to MyoD. Cell 1989;56:607-17.
44. Aurade F, Pinset C, Chafey P, et al. Myf5, MyoD, myogenin and MRF4 myogenic derivatives of the embryonic mesenchymal cell line C3H10T1/2 exhibit the same adult muscle phenotype. Differentiation 1994;55:185-92.
45. Weintraub H, Davis R, Tapscott S, et al. The MyoD gene family: nodal point during specification of muscle cell lineage. Science 1991;151:761-6.
46. Faerman A, Pearson-White S, Emerson C, et al. Ectopic expression of MyoD1 in mice causes prenatal lethalities. Dev Dyn 1993;196:165-73.
47. Tintignac LA, Leibovitch MP, Leibovitch SA. [New insight into MyoD regulation: involvement in rhabdomyosarcoma pathway?] Bull Cancer 2001;88:545-8.
48. Hosoi H, Sugimoto T, Hayashi Y, et al. Differential expression of myogenic regulatory genes, MyoD1 and myogenin, in human rhabdomyosarcoma sublines. Int J Cancer 1992;50:977-83.
49. Yablonka-Reuveni Z, Paterson BM. MyoD and myogenin expression patterns in cultures of fetal and adult chicken myoblasts. J Histochem Cytochem 2001;49:455-62.
50. Myer A, Olson EN, Klein WH. MyoD cannot compensate for the absence of myogenin during skeletal muscle differentiation in murine embryonic stem cells. Dev Biol 2001;229:340-50.
51. Nabeshima Y, Hanaoka K, Hayasaka M, et al. Myogenin gene disruption results in perinatal lethality because of severe muscle defect. Nature 1993;364:532-5.
52. Kahn HJ, Yeger H, Kassim O, et al. Immunohistochemical and electron microscopic assessment of childhood rhabdomyosarcoma. Increased frequency of diagnosis over routine histologic methods. Cancer 1983;51:1897-903.
53. Engel ME, Mouton SC, Emms M. Paediatric rhabdomyosarcoma: MyoD1 demonstration in routinely processed tissue sections using wet heat pretreatment [pressure cooking) for antigen retrieval. J Clin Pathol 1997;50:37-9.
54. Cessna M, Coffin C, Perkins S, et al. Myogenin (MYOG) and MyoD1 (MD1) expression in rhabdomyosarcoma (RMS) and spindle cell mimics: a study of 135 cases. Lab Invest 2001;81:36.
55. Cessna MH, Zhou H, Perkins SL, et al. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics. Am J Surg Pathol 2001;25:1150-7.
56. Kumar S, Perlman E, Harris CA, et al. Myogenin is a specific marker for rhabdomyosarcoma: an immunohistochemical study in paraffin-embedded tissues. Mod Pathol 2000;13:988-93.
57. Cui S, Hano H, Harada T, et al. Evaluation of new monoclonal anti-MyoD1 and anti-myogenin antibodies for the diagnosis of rhabdomyosarcoma. Pathol Int 1999;49:62-8.
58. Folpe AL. MyoD1 and myogenin expression in human neoplasia: a review and update. Adv Anat Pathol 2002;9:198-203.
59. Dias P, Chen B, Dilday B, et al. Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass. Am J Pathol 2000;156:399-408.
60. Williams S, Sebire NJ, Ramsay A, et al. Immunohistochemical expression of myogenin and MyoD1 in embryonal, classic alveolar and solid-variant paediatric alveolar rhabdomyosarcoma [abstract]. J Pathol 2002;198:25A.
61. Khan J, Bittner ML, Saal LH, et al. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci U S A 1999;96:13264-9.
62. Frascella E, Rosolen A. Detection of the MyoD1 transcript in rhabdomyosarcoma cell lines and tumor samples by reverse transcription polymerase chain reaction. Am J Pathol 1998;152:577-83.
63. Gattenloehner S, Dockhorn-Dworniczak B, Leuschner I, et al. A comparison of MyoD1 and fetal acetylcholine receptor expression in childhood tumors and normal tissues: implications for the molecular diagnosis of minimal disease in rhabdamyosarcomas. J Mol Diagn 1999;1:23-31.
64. Athale UH, Shurtleff SA, Jenkins JJ, et al. Use of reverse transcriptase polymerase chain reaction for diagnosis and staging of alveolar rhabdomyosarcoma, Ewlng sarcoma family of tumors, and desmoplastic small round cell tumor. J Pediatr Hematol Oncol 2001;23:99-104.